Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
We describe a bispecific dual-antagonist antibody against human B cell activating factor (BAFF) and interleukin 17A (IL-17). An anti-IL-17 single-chain variable fragment (scFv) derived from ixekizumab (Taltz®) was fused via a glycine-rich linker to anti-BAFF tabalumab. The IgG-scFv bound both BAFF and IL-17 simultaneously with identical stoichiometry as the parental mAbs. Stability studies of the initial IgG-scFv revealed chemical degradation and aggregation not observed in either parental antibody. The anti-IL-17 scFv showed a high melting temperature (Tm) by differential scanning calorimetry (73.1°C), but also concentration-dependent, initially reversible, protein self-association. To engineer scFv stability, three parallel approaches were taken: labile complementary-determining region (CDR) residues were replaced by stable, affinity-neutral amino acids, CDR charge distribution was balanced, and a H44-L100 interface disulfide bond was introduced. The Tm of the disulfide-stabilized scFv was largely unperturbed, yet it remained monodispersed at high protein concentration. Fluorescent dye binding titrations indicated reduced solvent exposure of hydrophobic residues and decreased proteolytic susceptibility was observed, both indicative of enhanced conformational stability. Superimposition of the H44-L100 scFv (PDB id: 6NOU) and ixekizumab antigen-binding fragment (PDB id: 6NOV) crystal structures revealed nearly identical orientation of the frameworks and CDR loops. The stabilized bispecific molecule LY3090106 (tibulizumab) potently antagonized both BAFF and IL-17 in cell-based and in vivo mouse models. In cynomolgus monkey, it suppressed B cell development and survival and remained functionally intact in circulation, with a prolonged half-life. In summary, we engineered a potent bispecific antibody targeting two key cytokines involved in human autoimmunity amenable to clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585 · cited 1×
“In recent years, multiple studies have established the pathogenic involvement of Th17 cells and its cytokine IL-17 in autoimmune diseases, including psoriasis, psoriatic arthritis, RA, ankylosing spondylitis, and multiple sclerosis.(15,16) Both IL-17 and its receptor have been targeted by an array of FDA-approved ther…”
BackgroundStructure and signalling in the IL-17 receptor family
Gaffen, S. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2586 · Cited by 1,475 · cited 1×
“The IL-17 family of cytokines contains six structurally related isoforms: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (IL-25), and IL17F with distinct abilities to form homo- or heterodimers, leading to differences in specificity and signaling potencies.(12,13) These cytokines are important for the control of infections, e…”
BackgroundInterleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409 · cited 1×
“In recent years, multiple studies have established the pathogenic involvement of Th17 cells and its cytokine IL-17 in autoimmune diseases, including psoriasis, psoriatic arthritis, RA, ankylosing spondylitis, and multiple sclerosis.(15,16) Both IL-17 and its receptor have been targeted by an array of FDA-approved ther…”
BackgroundAlternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Röthlisberger, D., Honegger, A., & Plückthun, A. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.01.053 · Cited by 289
B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis
François, A., Gombault, A., Villeret, B., Alsaleh, G., Fanny, M., Gasse, P., Adam, S. M., Crestani, B., Sibilia, J., Schneider, P., et al. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.08.003 · Cited by 109
Prediction of VH-VL domain orientation for antibody variable domain modeling
Bujotzek, A., Dunbar, J., Lipsmeier, F., Schäfer, W., Antes, I., Deane, C. M., & Georges, G. (2015) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24756 · Cited by 56
Weatherill, E. E., Cain, K. L., Heywood, S. P., Compson, J. E., Heads, J. T., Adams, R., & Humphreys, D. P. (2012) · Protein Engineering Design and Selection · doi:10.1093/protein/gzs021 · Cited by 42
Cited by
Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 259
Thera-SAbDab: the therapeutic structural antibody database
Raybould, M. I. J., Marks, C., Lewis, A. P., Shi, J., Bujotzek, A., Taddese, B., & Deane, C. M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkz827 · Cited by 199
“A significant fraction of these structures contain antibody variable domains, and these are recorded by the Structural Antibody Database (SAbDab (16); 7047 variable domain structures over 3620 PDB entries as of 18th July 2019).”
BackgroundInfluentialHallucinating structure-conditioned antibody libraries for target-specific binders
Mahajan, S. P., Ruffolo, J. A., Frick, R., & Gray, J. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.999034 · Cited by 20
“1CE1[38] Alemtuzumab 21 6BFT[39] Bevacizumab 74 6NOV[40] Ixekizumab 24 4LLU[41] Pertuzumab 85 5WUV[42] Certolizumab 100 5B8C[43] Pembrolizumab 34 6TCS[44] Omalizumab 36 5XXY[45] Atezolizumab 93 1N8Z[37] Trastuzumab 43”
Zhao, X., Ning, Q., Mo, Z., & Tang, S. (2019) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2019.1657875 · Cited by 16
Metadata
- Authors
- Benschop, R. J., Chow, C.-K., Tian, Y., Nelson, J., Barmettler, B., Atwell, S., Clawson, D., Chai, Q., Jones, B., Fitchett, J., Torgerson, S., Ji, Y., Bina, H., Hu, N., Ghanem, M., Manetta, J., Wroblewski, V. J., Lu, J., & Allan, B. W.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2019-06-10
- Volume
- 11
- Issue
- 6
- Pages
- 1175-1190
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2951033460
- Cited by
- 52
- References
- 8
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. https://app.cochat.ai/papers/10.1080/19420862.2019.1624463
- The paper
- Benschop, R. J., Chow, C.-K., Tian, Y., Nelson, J., Barmettler, B., Atwell, S., Clawson, D., Chai, Q., Jones, B., Fitchett, J., Torgerson, S., Ji, Y., Bina, H., Hu, N., Ghanem, M., Manetta, J., Wroblewski, V. J., Lu, J., & Allan, B. W. (2019). Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. mAbs. https://doi.org/10.1080/19420862.2019.1624463
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.